CureVac N.V. (FRA:5CV)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.06B |
| Revenue (ttm) | 523.70M |
| Net Income (ttm) | 180.66M |
| Shares Out | n/a |
| EPS (ttm) | 0.80 |
| PE Ratio | 5.85 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,450 |
| Average Volume | 16,495 |
| Open | 4.636 |
| Previous Close | 4.690 |
| Day's Range | 4.636 - 4.712 |
| 52-Week Range | 2.170 - 4.950 |
| Beta | n/a |
| RSI | 52.27 |
| Earnings Date | Aug 15, 2025 |
About DFS
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In ad... [Read more]
News
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled
GSK to be paid up to £370 million after patent row settles in US
CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on Thursday.
CureVac settles patent dispute litigation with Pfizer and BioNTech
CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.
CureVac Resolves Patent Dispute with Pfizer/BioNTech!
CureVac and GSK have settled patent disputes with BioNTech and Pfizer, securing $740 million and future royalties, while paving the way for global mRNA vaccine collaboration. Jetzt den vollständigen A...
EQS-News: CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech
Issuer: CureVac / Key word(s): Patent CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech 08.08.2025 / 02:15 CET/CEST The issuer is solely responsible for the content of this announ...
CureVac Announces Voting Results of General Meeting
TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on ...
CureVac's General Meeting: Key Voting Results Revealed!
The meeting underscored CureVac's commitment to advancing healthcare solutions through strategic leadership and global collaboration. Jetzt den vollständigen Artikel lesen
EQS-News: CureVac Announces Voting Results of General Meeting
Issuer: CureVac / Key word(s): AGM/EGM CureVac Announces Voting Results of General Meeting 24.06.2025 / 22:09 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac An...
Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges
Amarin Corporation Plc (NASDAQ: AMRN) on Tuesday entered into an exclusive long-term license and supply agreement with Recordati S.p.A. , Italy, to commercialize Vazkepa (icosapent ethyl) in 59 count...
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CureVac N.V. (NASDAQ: CVAC)
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and ...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breac...
This Sherwin-Williams Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
BioNTech's Acquisition Of CureVac Brings Complementary Method To Target Cancer
The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA candidates. Click for my look at BNTX and CVAC.
Stocks making the biggest midday moves: Oracle, Boeing, CureVac, Datadog and more
Here are the stocks making headlines in Thursday's trading.
Top Stock Movers Now: Oracle, Boeing, CureVac, and More
U.S. equities were mixed and little changed at midday as a second inflation report this week came in lower than anticipated.
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech SE (NASDAQ: BNTX) on Thursday agreed to acquire CureVac N.V. (NASDAQ: CVAC) in an all-stock transaction . According to the agreement, shareholders can exchange CureVac shares for around $5....
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.
CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Thursday. Shares of CureVac N.V. (NASDAQ: CVAC) rose sharply during Thursday's session after BioNTech announced it will acquir...
Stocks to Watch Thursday: Boeing, Oracle, Oklo, CureVac
COVID-19 Vaccine Maker BioNTech Buys CureVac as It Aims for Cancer Treatments
CureVac shares skyrocketed 35% Thursday when the biotech firm agreed to be bought by COVID-19 vaccine maker BioNTech in an all-stock deal valued at about $1.25 billion.
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CureVac N.V. (NASDAQ: CVAC) to BioNTech SE is fair to CureVac shareholders. Under the terms of the proposed transact...
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CureVac N.V. (NASDAQ: CVAC) to BioNTech SE is fair to CureVac shareholders. Under the ter...
BioNTech to Acquire CureVac in Stock Deal Valued Around $1.25 Billion
BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.
CureVac stock soared 29% $5.26 in premarket trading immediately following the news.
BioNTech to acquire CureVac in $1.25 billion all-stock deal
German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.